Spero Therapeutics Restructures Focus on Key R&D Projects
Company Announcements

Spero Therapeutics Restructures Focus on Key R&D Projects

Spero Therapeutics ( (SPRO) ) has shared an update.

Spero Therapeutics announced a significant workforce reduction to realign focus on tebipenem HBr and other R&D projects after the SPR720 trial for NTM-PD didn’t meet its primary endpoint. The restructuring aims to extend the company’s cash runway into mid-2026, supporting ongoing trials and strategic initiatives. The company remains committed to advancing its pipeline, including the PIVOT-PO Phase 3 trial for tebipenem HBr, amidst potential challenges and the need for further funding.

For a thorough assessment of SPRO stock, go to TipRanks’ Stock Analysis page.

Related Articles
Brian AndersonSPRO Upcoming Earnings Report: What to Expect?
TheFlySpero Therapeutics price target lowered to $5 from $7 at H.C. Wainwright
TheFlyBiotech Alert: Searches spiking for these stocks today
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App